Small Stocks, Big Money™

Enlivex Therapeutics (Nasdaq: ENLV) reported positive interim six-month data from its Phase I/II trial of Allocetra™, showing a statistically significant 47% reduction in pain (P=0.0001) in patients with moderate to severe knee osteoarthritis. The results also demonstrated a 46% improvement in joint function and 40% improvement in stiffness, with 83% of patients still responding to treatment at six months—all with no serious adverse events. The durability of these results reinforces Allocetra™’s potential as a long-lasting, non-surgical solution for osteoarthritis sufferers. With Phase II enrollment underway and a topline readout expected in Q3 2025, Enlivex is advancing toward a potential breakthrough in osteoarthritis treatment.

Jupiter Neurosciences (Nasdaq: JUNS) is expanding into the rapidly growing longevity and healthspan market through a strategic partnership with Aquanova AG. The collaboration will leverage JOTROL™, Jupiter’s proprietary resveratrol-based platform, and Aquanova’s NovaSOL™ technology to develop scientifically backed consumer health products that enhance aging and wellness. The first three products are set to launch in Q3 2025 via a direct-to-consumer model, providing near-term revenue growth while Jupiter continues advancing its Phase IIa clinical trials for Parkinson’s Disease and other CNS disorders. By launching these products under a new wholly owned subsidiary, Jupiter is creating an immediate commercial pathway while maintaining its long-term pharmaceutical development focus.

ConnectM Technology Solutions (Nasdaq: CNTM) is expanding its Building Electrification segment into Europe, the Middle East, and Asia, capitalizing on rising energy costs and government-backed clean energy initiatives. With AI-powered energy optimization solutions, ConnectM aims to become a market leader in digital-first electrification, helping buildings transition to sustainable heating, cooling, and distributed energy systems. The company has already built a strong pipeline of demand in these regions and expects its international operations to drive multiple revenue streams by early 2026. This strategic expansion positions ConnectM at the forefront of the global shift toward electrification and energy efficiency.

VSee Health (Nasdaq: VSEE) secured a $444K contract with one of the largest U.S. counties to deploy a customized telehealth and data analytics platform for mental and behavioral health services. This win strengthens VSee’s public sector presence, demonstrating its ability to deliver scalable, compliance-ready healthcare technology to underserved populations. VSee’s modular platform enables rapid deployment, AI-driven provider matching, and HIPAA-compliant telehealth solutions—ensuring secure, accessible care for low-tech and no-tech demographics. With a growing footprint in high-value, recurring government contracts, VSee is positioning itself as a key player in digital healthcare infrastructure.